Publication | Closed Access

Kegan Liyan oral liquid ameliorates lipopolysaccharide-induced acute lung injury through inhibition of TLR4-mediated NF-κB signaling pathway and MMP-9 expression

InflammationAcute Lung InjuryTlr4-mediated Nf-κbMmp-9 ExpressionInflammatory Lung DiseaseAnti-inflammatoryLung InflammationMedicineImmunologyChronic InflammationPulmonary PharmacologyPulmonary FibrosisInnate ImmunityImmune FunctionPharmacologyCell Signaling